Immuneering (NASDAQ:IMRX) Posts Earnings Results, Misses Expectations By $0.01 EPS

Immuneering (NASDAQ:IMRX) issued its quarterly earnings results on Wednesday. The company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.01), FiscalAI reports.

Immuneering Price Performance

Shares of NASDAQ IMRX traded down $0.07 during mid-day trading on Wednesday, hitting $4.33. The company had a trading volume of 267,628 shares, compared to its average volume of 1,435,873. Immuneering has a 12 month low of $2.90 and a 12 month high of $10.08. The stock has a market cap of $280.47 million, a price-to-earnings ratio of -3.71 and a beta of 0.43. The firm’s 50 day simple moving average is $4.62 and its two-hundred day simple moving average is $4.99.

Analyst Upgrades and Downgrades

IMRX has been the subject of several recent analyst reports. Chardan Capital reissued a “buy” rating and set a $20.00 price objective on shares of Immuneering in a report on Tuesday, May 19th. Oppenheimer reissued an “outperform” rating on shares of Immuneering in a report on Monday, June 1st. Cantor Fitzgerald initiated coverage on Immuneering in a report on Wednesday, July 8th. They set an “overweight” rating and a $17.00 target price on the stock. Wall Street Zen lowered Immuneering from a “hold” rating to a “sell” rating in a research report on Monday, July 20th. Finally, Needham & Company LLC upped their price target on Immuneering from $11.00 to $18.00 and gave the company a “buy” rating in a research report on Monday, July 20th. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $17.57.

Institutional Investors Weigh In On Immuneering

Hedge funds have recently added to or reduced their stakes in the stock. Barclays PLC grew its position in shares of Immuneering by 943.2% during the fourth quarter. Barclays PLC now owns 230,726 shares of the company’s stock worth $1,518,000 after acquiring an additional 208,608 shares during the last quarter. State Street Corp lifted its position in Immuneering by 1,289.7% in the 4th quarter. State Street Corp now owns 2,402,238 shares of the company’s stock valued at $15,807,000 after purchasing an additional 2,229,374 shares during the last quarter. Geode Capital Management LLC lifted its position in Immuneering by 20.3% in the 4th quarter. Geode Capital Management LLC now owns 618,074 shares of the company’s stock valued at $4,068,000 after purchasing an additional 104,409 shares during the last quarter. Burkehill Global Management LP acquired a new position in Immuneering during the 3rd quarter valued at about $2,100,000. Finally, Southport Management L.L.C. boosted its stake in Immuneering by 1.8% during the 4th quarter. Southport Management L.L.C. now owns 277,501 shares of the company’s stock valued at $1,826,000 after purchasing an additional 5,000 shares during the period. 67.65% of the stock is currently owned by institutional investors.

About Immuneering

Immuneering (Nasdaq: IMRX) is a clinical-stage biopharmaceutical company leveraging artificial intelligence and its proprietary RABIT (Repurposing and Accelerating Biotechnology Tools) platform to design and optimize small-molecule and peptide therapies. By analyzing large-scale biomedical datasets, Immuneering’s machine learning algorithms identify novel drug–target interactions, repurpose existing drug scaffolds and accelerate lead candidate selection. The company’s AI-driven approach aims to reduce development timelines and improve therapeutic profiles in areas of high unmet medical need.

The company’s lead program, IRX-2, is a small-molecule candidate currently in Phase 2 clinical trials for the treatment of painful diabetic peripheral neuropathy.